Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 10/20 | 0.56 |
| ▸ | TEK | Q02763 | 4/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.54 |
| ▸ | BRAF | P15056 | 3/20 | 0.54 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.52 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.52 |
| ▸ | GCGR | P47871 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490139 | 0.91 | RAF1 (0.69) | RAF1TEKMAPK14MAPK13MAPK12 | |
| SCHEMBL4472619 | 0.91 | NOX1 (0.53) | RAF1TEKMAPK14MAPK13MAPK12 | |
| SCHEMBL4467742 | 0.89 | RAF1 (0.64) | RAF1TEKMAPK14MAPK13MAPK12 | |
| SCHEMBL4468775 | 0.87 | MAPT (0.53) | RAF1TEKMAPK14MAPK13MAPK12 | |
| SCHEMBL4467748 | 0.84 | ALOX5 (0.52) | RAF1TEKMAPK14MAPK13MAPK12 | |
| SCHEMBL4483579 | 0.84 | ALOX5 (0.49) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4468049 | 0.78 | KDM4E (0.45) | RAF1TEKMAPK14MAPK13MAPK12 | |
| SCHEMBL4471392 | 0.77 | MAPK14 (0.79) | RAF1TEKMAPK14MAPK13MAPK12 | |
| SCHEMBL4474775 | 0.77 | RAF1 (0.54) | RAF1TEKMAPK14MAPK13MAPK12 | |
| SCHEMBL6466096 | 0.76 | RAF1 (0.68) | RAF1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569593-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-08-04 | — | — | US | claimed |
| EP-1670780-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-12-17 | — | — | EP | claimed |
| EP-1670780-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-06-21 | — | — | EP | claimed |
| US-20050209285-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-09-22 | — | — | US | claimed |
| WO-2005030151-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (US) | 2005-04-07 | — | — | WO | claimed |
| EP-0980369-B1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | ENCYSIVE PHARMACEUTICALS INC (US) | 2005-03-30 | — | — | EP | claimed |
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | IRM LLC (BM) | 2009-10-15 | — | — | US | disclosed |
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | IRM LLC (BM) | 2009-10-15 | — | — | US | disclosed |
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | IRM LLC (BM) | 2009-10-15 | — | — | US | disclosed |
| US-7569593-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-08-04 | — | — | US | disclosed |
| US-7569593-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-08-04 | — | — | US | disclosed |
| US-7569593-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-08-04 | — | — | US | disclosed |
| EP-1670780-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-12-17 | — | — | EP | disclosed |
| WO-2005030151-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-0980369-B1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | ENCYSIVE PHARMACEUTICALS INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1498418-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1498419-A1 | Process for preparing alkali metal salts of hydrophobic sulfonamides | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6683103-B2 | SULFONAMIDES CONTAINING OXAZOLE AND SUBSTITUTED THIOPHENE RINGS, USEFUL FOR TREATING HYPERTENSION, CARDIOVASCULAR DISEASE, ASTHMA, PULMONARY HYPERTENSION, INFLAMMATORY DISEASES, VISION DEFECTS, MENSTRUAL DISORDERS, RENAL FAILURE | TEXAS BIOTECHNOLOGY CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-6432994-B1 | CARDIOVASCULAR DISORDERS, GLAUCOMA; ANTIINFLAMMATORY, WOUND HEALING, HYPOTENSIVE, ANTIASTHMATIC, AND ANTIANAPHYLACTIC AGENTS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | PDGFRA, RAF1, FLT1 | RAF1 2/4885TEK 73/4885MAPK14 129/4885 |
| US-20050209285-A1 | Compounds and compositions as protein kinase inhibitors | LCK, RAF1, MAP3K1 | RAF1 2/4885TEK 115/4885MAPK14 68/4885 |
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | EDNRA, ECE1, EDNRB | RAF1 2355/4885TEK 1231/4885MAPK14 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.